

Yong Wha Moon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6197003/publications.pdf>

Version: 2024-02-01

18
papers

824
citations

933447

10
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

1685
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase. <i>Cancers</i> , 2022, 14, 210.	3.7	8
2	Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1223.	4.1	16
3	Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics. <i>Genes</i> , 2021, 12, 159.	2.4	16
4	Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence. <i>Cancers</i> , 2020, 12, 3566.	3.7	66
5	Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model. , 2020, 8, e001513.		17
6	Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3590-3590.	1.6	12
7	Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (<i>MET</i>^{Amp/Ex14}).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9510-9510.	1.6	21
8	[OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1106-TPS1106.	1.6	4
9	Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies. <i>Yonsei Medical Journal</i> , 2020, 61, 844.	2.2	7
10	IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells. , 2019, 7, 168.		58
11	A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 153, 135-148.	1.4	45
12	Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. <i>International Journal of Cancer</i> , 2019, 145, 1179-1188.	5.1	199
13	Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma. <i>European Journal of Radiology</i> , 2018, 101, 118-123.	2.6	17
14	High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 116, 38-45.	2.0	21
15	CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator. <i>Oncotarget</i> , 2018, 9, 2622-2630.	1.8	13
16	PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS587-TPS587.	1.6	6
17	Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution. <i>PLoS ONE</i> , 2016, 11, e0154133.	2.5	12
18	Targeting the indoleamine 2,3-dioxygenase pathway in cancer. , 2015, 3, 51.		280